Literature DB >> 7918476

Determination of kinetic rate constants for the binding of inhibitors to HIV-1 protease and for the association and dissociation of active homodimer.

C A Pargellis1, M M Morelock, E T Graham, P Kinkade, S Pav, K Lubbe, D Lamarre, P C Anderson.   

Abstract

Association and dissociation rate constants for a competitive inhibitor of HIV-1 protease were determined by a novel method employing a pair of integrated rate equations. This method, termed the paired progress curve method, is both rapid and reproducible. Progress curves, taken at a single concentration of inhibitor, are analyzed simultaneously to determine association and dissociation rate constants, the concentration of active sites, and the catalytic rate constant. The method is applied to BILA 398, a compound for which the cocrystal structure with HIV-2 protease has been reported recently [Tong, L., et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 8387-8391]. This compound exhibited an association constant of 1.6 x 10(7) M-1 s-1 and a dissociation constant of 1.0 x 10(-4) s-1 corresponding to a binding affinity constant of 6.4 x 10(-12) M. During the course of the analysis, nonlinearity was observed in control reactions containing enzyme and substrate only. This was subsequently shown to be due to a reversible inactivation process resulting from enzyme dilution. Integrated rate equations were developed on the basis of the dissociation of active dimeric enzyme during dilution and a reassociation of dilute monomers following the addition of substrate. The equations were modeled to the data, yielding a dissociation constant of 1.9 x 10(-3) s-1 and an association constant of 9.2 x 10(5) M-1 s-1 for the monomer-dimer interconversion process. This corresponds to an equilibrium constant of 4 x 10(-9) M for the dimerization of HIV-1 protease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7918476     DOI: 10.1021/bi00207a021

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.

Authors:  L Doyon; G Croteau; D Thibeault; F Poulin; L Pilote; D Lamarre
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

2.  Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication.

Authors:  A H Kaplan; M Manchester; T Smith; Y L Yang; R Swanstrom
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

3.  Trp42 rotamers report reduced flexibility when the inhibitor acetyl-pepstatin is bound to HIV-1 protease.

Authors:  B Ullrich; M Laberge; F Tölgyesi; Z Szeltner; L Polgár; J Fidy
Journal:  Protein Sci       Date:  2000-11       Impact factor: 6.725

4.  Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.

Authors:  D Lamarre; G Croteau; E Wardrop; L Bourgon; D Thibeault; C Clouette; M Vaillancourt; E Cohen; C Pargellis; C Yoakim; P C Anderson
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.

Authors:  G Croteau; L Doyon; D Thibeault; G McKercher; L Pilote; D Lamarre
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

6.  Kinetics of the dimerization of retroviral proteases: the "fireman's grip" and dimerization.

Authors:  Marek Ingr; Tat'ána Uhlíková; Kvido Strísovský; Eva Majerová; Jan Konvalinka
Journal:  Protein Sci       Date:  2003-10       Impact factor: 6.725

7.  Current and Novel Inhibitors of HIV Protease.

Authors:  Jana Pokorná; Ladislav Machala; Pavlína Rezáčová; Jan Konvalinka
Journal:  Viruses       Date:  2009-12-11       Impact factor: 5.048

8.  Inhibitor and substrate binding induced stability of HIV-1 protease against sequential dissociation and unfolding revealed by high pressure spectroscopy and kinetics.

Authors:  Marek Ingr; Reinhard Lange; Věra Halabalová; Alaa Yehya; Josef Hrnčiřík; Dominique Chevalier-Lucia; Laetitia Palmade; Claire Blayo; Jan Konvalinka; Eliane Dumay
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.